News for Sosei Group Corporation (SOLTF)

The rise in research and development activities in schizophrenia treatment is driving market growth by fostering the development of innovative therapies,...

By Jonathan Trevor and Kazuhiro Asakawa In the first of a two-part series, we explore how firms are reaping the benefits of leveraging a network of external resources for enhanced […]

Effective April 01, 2024, Sosei Group Corporation will change its name to Nxera Pharma Co., Ltd....

Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma

Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously...

Tokyo, Japan and Cambridge, UK, 6 March 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) announces that Formosa...

Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results...

Tokyo, Japan and Cambridge, UK, 5 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces the appointment of...

Shared Research, Inc. Issued an Analyst Report on Sosei Group Corporation Attachments Original Link Original Document ...

Tokyo, Japan and Cambridge, UK, 21 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), announces its President &...

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the fourth quarter and fiscal year ended December 31,...

INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $399 MillionINGREZZA® (valbenazine) 2023 Net Product Sales Guidance of $1.67 - $1.77 B...